Esperion Therapeutics (ESPR) Inventory Average (2020 - 2026)

Esperion Therapeutics has reported Inventory Average for 7 years, with the latest figure at $104.7 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 8.01% year-over-year to $104.7 million; the trailing twelve-month figure through Mar 2026 stood at $104.7 million (up 8.01% YoY), and the FY2025 full-year result was $99.8 million, up 24.67% from the prior year.
• Inventory Average for Q1 2026 stood at $104.7 million, down from $106.8 million in the prior quarter.
• The five-year high for Inventory Average was $111.5 million in Q3 2025, with the low at $29.4 million in Q3 2022.
• Historically, Inventory Average has averaged $68.3 million across 5 years, with a median of $69.4 million in 2024.
• The largest YoY upside for Inventory Average was 93.68% in 2022 against a maximum downside of 5.3% in 2022.
• Esperion Therapeutics' Inventory Average stood at $32.4 million in 2022, then jumped by 80.8% to $58.5 million in 2023, then surged by 49.15% to $87.3 million in 2024, then advanced by 22.38% to $106.8 million in 2025, then dropped by 2.03% to $104.7 million in 2026.
• The last three Inventory Average figures came in at $104.7 million (Q1 2026), $106.8 million (Q4 2025), and $111.5 million (Q3 2025), per Business Quant data.